Abstract
There has been a constant endeavor to reduce the mortality and morbidity associated
with acute brain injury. The associated complex mechanisms involving biomechanics,
markers, and neuroprotective drugs/measures have been extensively studied in preclinical
studies with an ultimate aim to improve the patients' outcomes. Despite such efforts,
only few have been successfully translated into clinical practice. In this review,
we shall be discussing the major hurdles in the translation of preclinical results
into clinical practice. The need is to choose an appropriate animal model, keeping
in mind the species, age, and gender of the animal, choosing suitable outcome measures,
ensuring quality of animal trials, and carrying out systematic review and meta-analysis
of experimental studies before proceeding to human trials. The interdisciplinary collaboration
between the preclinical and clinical scientists will help to design better, meaningful
trials which might help a long way in successful translation. Although challenging
at this stage, the advent of translational precision medicine will help the integration
of mechanism-centric translational medicine and patient-centric precision medicine.
Keywords
acute brain injury - translational research - subarachnoid hemorrhage - traumatic
- brain injury - acute ischemic stroke
